CompletedPhase 3

Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

United States45 participantsStarted 2022-04-14

Plain-language summary

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of imsidolimab compared with placebo in adult subjects with generalized pustular psoriasis (GPP).

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: \- Subject has a BSA affected with pustules (excluding palms and soles) ≥ 5%, a GPPPGA score ≥ 3 (moderate severity), and a PRS score ≥ 3 (moderate severity) at Day 1 Exclusion Criteria: * Subject has other form of psoriasis excluding psoriasis vulgaris * Subject flare is so severe that patient's life is at risk

What they're measuring

Percentage of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear)

Timeframe: Week 4

Trial details

NCT IDNCT05352893

SponsorVanda Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2023-08-17

Results submitted2026-01-23

View on ClinicalTrials.gov More Generalized Pustular Psoriasis trials